You are currently viewing WHO Says CureVac Results “Disappointing,” But Testing Needs To Be Followed

The chief scientist of the WHO, Soumya Swaminathan, acknowledged this Friday that the new efficacy data for the coronavirus vaccine developed by the German firm CureVac (47%) are “disappointing”, Although he pointed out that it is common for not all investigations to be successful and encouraged further investigation.

The results are below the 50 percent limit we had set, so it is disappointing”Admitted the Indian expert at a press conference, noting that it was especially striking given that previous vaccines with the new messenger RNA technology, such as those from Pfizer or Moderna, had been successful.

  • WHO: “Delta variant of coronavirus is becoming more prominent and dominant in the world”
  • Global coronavirus infections down for the seventh consecutive week but up in Africa
  • The G7 calls for a more in-depth and “transparent” study by the WHO on the “origins of COVID-19” in China

This warns us of something important, that in the development of vaccines not all will have the same results, and we cannot assume that all messenger RNA vaccines will respond in the same way”, Assured the representative of the World Health Organization.

Swaminathan indicated that the CureVac It initially offered certain advantages, such as the fact that it could be stored without the need for ultra-cold temperatures.

The chief scientist of the World Health Organization (WHO), Soumya Swaminathan, during a press conference in Geneva, Switzerland, on July 3, 2020. (File photo: Reuters) (Reuters Agency /)

The poor results in vaccine tests, he said, “They are something normal”. “Actually, we have been very fortunate to have so many successful vaccines.”, He said in reference to the approximately a dozen pharmaceutical companies that are already distributing their doses globally.

We must continue to support research into vaccine candidates, particularly those that are easier to use.”, He concluded, calling for prioritizing those that are easy to store, those that can be administered in a single dose or those that do not need to be injected (for example, those that allow the oral route).

The second preliminary analysis of the vaccine CureVac was only 47% effective in preventing COVID-19, something that caused the German biopharmaceutical to crash on the stock market.

RECOMMENDED VIDEO

IT MAY INTEREST YOU

  • The giant sinkhole begins to swallow a house in Mexico | PHOTOS
  • Facebook suspends Donald Trump until 2023
  • How is the innovative nuclear reactor “Natrium” that Bill Gates and Warren Buffett will build in the US?
  • The majority of patients with coronavirus in Chile did not want to be vaccinated
  • “¡Miserables!”: Maduro criticizes the US for excluding Venezuela from donating vaccines
  • The luxuries of Nicolás Maduro: the payment of US $ 60,000 to the singer Bonny Cepeda and other waste in recent years

.

Disclaimer: If you need to update/edit/remove this news or article then please contact our support team Learn more